Peter O’Donnell, MD of @UChicagoMed provides results from biomarkers in patients with locally advanced metastatic urothelial carcinoma treated with durvalumab in phase 1/2 doseâ€escalation.
Biomarkers with Locally Advanced Metastatic Carcinoma Results
